2023
Current use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study
Miller S, Azar S, Farrelly J, Salzman G, Broderick M, Sanders K, Anto V, Patel N, Cordova A, Schuster K, Jones T, Kodadek L, Gross C, Morton J, Rosenthal R, Becher R. Current use of the National Surgical Quality Improvement Program surgical risk calculator in academic surgery: a mixed-methods study. Surgery In Practice And Science 2023, 13: 100173. PMID: 37502700, PMCID: PMC10373440, DOI: 10.1016/j.sipas.2023.100173.Peer-Reviewed Original ResearchNSQIP Surgical Risk CalculatorSurgical Risk CalculatorNonelective casesRisk calculatorNational Surgical Quality Improvement Program Surgical Risk CalculatorHigh-risk patientsGeneral clinical practiceSpecific clinical scenariosCross-sectional studyElectronic health recordsFrail patientsPrimary outcomeHalf of respondentsPreoperative assessmentContemporary surgical practiceClinical practiceClinical scenariosSurgical practicePast monthPatientsSurgeonsTraining statusSurrogate consentPotential interventionsHealth records
2020
Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.
Parikh R, Cohen R, Min E, Wileyto E, Riaz F, Gross C, Long Q, Mamtani R. Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Journal Of Clinical Oncology 2020, 38: e19316-e19316. DOI: 10.1200/jco.2020.38.15_suppl.e19316.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced solid malignanciesEastern Cooperative Oncology Group performance statusUrothelial cell carcinomaRenal cell carcinomaNon-frail patientsFrail patientsSolid malignanciesHepatocellular carcinomaCell carcinomaFlatiron Health electronic health record-derived databaseStage IV non-small cell lung cancerElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsFirst-line ICI treatmentFirst-line systemic therapyImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsRetrospective cohort studyFirst-line useElixhauser Comorbidity IndexCell lung cancerMultivariable logistic regressionYears of treatment